natgillin/translations-raw huggingface dataset:
The objective response rate (complete response [CR] plus partial response [PR]) per independent radiological review was significantly (p<0.0001) higher in the lenvatinib-treated group (64.8%) than in the placebo-treated group (1.5%).
Objektivna odzivnost (popolni odziv [CR] plus delni odziv [PR]) po neodvisnem radiološkem pregledu je bila značilno (p<0,0001) večja v skupini, zdravljeni z lenvatinibom (64,8 %), kot v skupini, ki je prejemala placebo (1,5 %).
The objective response rate (ORR) in the Cotellic plus vemurafenib arm was 67.6% vs 44.8% in the placebo plus vemurafenib arm.
Objektivni delež odziva (ORR) je bil v skupini z zdravilom Cotellic in vemurafenibom 67,6 % v primerjavi s 44,8 % v skupini s placebom in vemurafenibom.
The objective response rate (ORR) in those patients who were tumour and ctDNA mutation positive was 77% (95% CI: 66% to 86%) and in those who were tumour only mutation positive 60% (95% CI: 44% to 74%).
Objektivni delež odziva (Objective response rate – ORR) pri bolnikih s pozitivno tumorsko in ctDNK mutacijo je bil 77 % (95 % IZ: od 66 % do 86 %), pri bolnikih, ki so imeli pozitivno mutacijo le na tumorju pa 60 % (95 % IZ: 44 % do 74 %).
The objective response rate by RECIST in the Tarceva group was 8.9% (95% CI, 6.4 to 12.0).
Objektivni odgovor na zdravljenje po kriterijih RECIST (Response Evaluation Criteria In Solid Tumours) je v skupini, ki je jemala zdravilo Tarceva, znašal 8,9 % (95-% interval zaupanja; 6,4 do 12,0).
The objective was to evaluate the ECG effects of IV administered palonosetron at single doses of 0.25, 0.75 or 2.25 mg in 221 healthy subjects.
Namen je bil oceniti učinke i.v. danega palonosetrona v enkratnih odmerkih po 0,25, 0,75 ali 2,25 mg na EKG pri 221 zdravih osebah.
The objectives of the programme are: to provide information on the administration of Sialanar, specifically on the accurate use of the prescribed dosing, the time of administration before the meals, the avoidance of the administration of Sialanar with high fat meals, use of the oral syringe and the need to complete the administration table at the end of the reminder card for patient's carer to remind the carer of the correct dose to be given to the child.
Cilji programa so: zagotoviti informacije o uporabi zdravila Sialanar, zlasti o uporabi pravilnega predpisanega odmerka, času uporabe pred obroki, izogibanju uporabe zdravila Sialanar pri obrokih z visoko vsebnostjo maščob, uporabi brizge za peroralno odmerjanje in potrebi po izpolnitvi preglednice o dajanju zdravila na koncu opozorilne kartice za skrbnika, da se ga opomni, da mora otroku dati pravilen odmerek;
The observed adverse drug reactions were overall similar to those seen in adults (see section 4.8).
Opaženi neželeni učinki zdravila so bili na splošno podobni tistim pri odraslih (glejte poglavje 4.8).
The observed adverse effect level for embryo-foetal toxicity in this study was 10 µg/kg/day, which corresponded to a systemic exposure of approximately 3 – 5 times the exposures observed in patients treated with the clinical dose.
Odmerek z ugotovljenimi neželenimi učinki, povezanimi s toksičnimi učinki na zarodek oz. plod, je bil v tej študiji 10 µg/kg/dan, kar ustreza sistemski izpostavljenosti, ki je približno 3 – 5-krat večja od izpostavljenosti bolnikov, zdravljenih s kliničnim odmerkom.
The observed adverse reactions for roflumilast in Study RO-2455- 404-RD were in line with those already included in section 4.8.
Neželeni učinki roflumilasta, ki so jih opazili v študiji RO-2455-404-RD, so bili v skladu s tistimi, ki so že navedeni v poglavju 4.8.
The observed adverse reactions from a pediatric clinical trial with the H5N1 vaccine are listed below.
V nadaljevanju so navedeni neželeni učinki, opaženi v pediatričnem kliničnem preskušanju cepiva proti H5N1.
The observed adverse reactions which occurred more frequently with lenalidomide and dexamethasone than placebo and dexamethasone in pooled multiple myeloma clinical trials (MM-009 and MM-010) were fatigue (43.9%), neutropenia (42.2%), constipation (40.5%), diarrhoea (38.5%), muscle cramp (33.4%), anaemia (31.4%), thrombocytopenia (21.5%), and rash (21.2%).
Neželeni učinki, ki so se pogosteje pojavili z lenalidomidom in deksametazonom kot s placebom in deksametazonom v združenih kliničnih preskušanjih pri diseminiranem plazmocitomu (MM-009 in MM-010), so bili utrujenost (43,9%), nevtropenija (42,2%), zaprtje (40,5%), driska (38,5%), mišični krči (33,4%), anemija (31,4%), trombocitopenija (21,5%) in izpuščaj (21,2%).
The observed difference in HbA1c over placebo was -0.72% after 52 weeks.
Po 52 tednih je bila opažena razlika v vrednosti HbA1c v primerjavi s placebom -0,72 %.
The observed drug accumulation index is  2 times with once daily dosing, suggesting an effective accumulation half-life of about 24 hours.
Pri odmerjanju enkrat na dan je bil opažen  2- kraten indeks akumulacije zdravila, kar kaže na približno 24-urno efektivno razpolovno dobo akumulacije.
The observed effect of selexipag versus placebo on the primary endpoint was consistent across individualised maintenance dose as shown by the hazard ratio for the three pre-defined categories (0.60 for 200–400 micrograms twice daily, 0.53 for 600–1,000 micrograms twice daily, and 0.64 for 1,200–1,600 micrograms twice daily), which was consistent with the overall treatment effect (0.60).
Opaženi učinek seleksipaga v primerjavi s placebom na primarni opazovani dogodek je bil konsistenten za vse individualne vzdrževalne odmerke, kot prikazuje razmerje tveganj za tri vnaprej določene kategorije (0,60 za 200–400 mikrogramov dvakrat na dan, 0,53 za 600–1.000 mikrogramov dvakrat na dan in 0,64 za 1.200–1.600 mikrogramov dvakrat na dan), ki je bil skladen s celokupnim učinkom zdravljenja (0,60).
The observed excess risk of fractures for women in this dataset on pioglitazone is, therefore, 0.8 fractures per
Opaženo čezmerno tveganje za zlome pri ženskah v tem naboru podatkov za pioglitazon je tako
The observed excess risk of fractures for women on pioglitazone in this study is therefore 0.5 fractures per 100 patient years of use.
Povečano tveganje za zlome pri ženskah zdravljenih s pioglitazonom opaženo v tej študiji, je torej 0,5 zlomov na 100 bolniških let uporabe.
The observed frequency is in line with control groups and prevalence reported in literature for symptomatic pre- menopausal women of this age group (mean of 40 years).
Opažena pogostost je bila skladna s kontrolnimi skupinami in prevalenco, o kateri poročajo v literaturi, pri simptomatskih ženskah pred menopavzo v tej starostni skupini (povprečno 40 let).
The observed geometric mean ratios of Viramune prolonged-release to Viramune immediate-release were ~90 % for Cmin,ss and AUCss with 90 % confidence intervals within 80 %-125 %; the ratio for Cmax,ss was lower and consistent with a once-daily prolonged-release dosage form.
Geometrični srednji razmerji med zdravilom Viramune s podaljšanim sproščanjem in zdravilom Viramune s takojšnjim sproščanjem sta bili ~90 % za Cmin,ss in AUCss ob 90-odstotnem intervalu zaupanja znotraj 80 do 125 %; razmerje za Cmax,ss je bilo nižje in se je ujemalo z obliko s podaljšanim sproščanjem za zdravljenje z enim odmerkom.
The observed group C booster response with Nimenrix was similar to that observed in subjects primed and boosted with a monovalent MenC-CRM conjugate vaccine.
Opažen odziv na obnovitveni odmerek cepiva Nimenrix proti skupini C je bil podoben tistemu, ki so ga opazili pri preskušancih, ki so prejeli osnovno in obnovitveno cepljenje z monovalentnim konjugiranim cepivom MenC-CRM.
The observed improvement in OS seen with G+B was supported by a stratified HR for OS of 0.62 (95% CI: 0.39, 0.98) in this post hoc analysis.
Opaženo izboljšanje celokupnega preživetja v skupini G + B podpira stratificirano razmerje ogroženosti (RO) za celokupno preživetje, ki je za to analizo post hoc 0,62 (95-% interval zaupanja: 0,39; 0,98).
The observed incidence of antibody positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications and underlying disease, therefore, comparison of the incidence of antibodies to other products may be misleading.
Na ugotovljeno incidenco pozitivnih izvidov za protitelesa z določenim preizkusom lahko vpliva več dejavnikov, med drugim metodologija preizkusa, ravnanje z vzorcem, čas odvzema vzorca, sočasno uporabljana zdravila in osnovna bolezen, zato je lahko primerjava incidence protiteles z drugimi zdravili zavajajoča.
The observed incidence of hypoglycaemia in patients treated with linagliptin was similar to placebo.
Pojavnost hipoglikemije je bila med zdravljenjem z linagliptinom podobna kot pri placebu.
The observed incidence of hypoglycaemia in patients treated with linagliptin was similar to placebo.
Pojavnost hipoglikemije je bila pri bolnikih, ki so jemali linagliptin, podobna kot pri placebu.
The observed incidence of hypoglycaemia in patients treated with linagliptin was similar to placebo.
Ugotovljena pojavnost hipoglikemije je bila pri bolnikih, ki so jemali linagliptin, podobna kot pri bolnikih, ki so jemali placebo.
The observed incidence of major and of minor non-ICH bleeds were similar in both groups:
Pojavnost velikih in manjših neintrakranialnih krvavitev je bila v obeh skupinah podobna
The observed incidence of the less severe form of neutropenia (neutrophils <1.5x109/l) is 4.9% (2.5 cases per 100 patient-years).
Opažena pojavnost manj resne oblike nevtropenije (vrednost nevtrofilcev < 1,5 x 109/l) je 4,9 % (2,5 pojavov bolezni na 100 bolnikov-let).
The observed incidence of the less severe form of neutropenia (neutrophils <1.5x109/l) is 4.9% (2.5 cases per 100 patient-years).
Opažena pojavnost manj resne oblike nevtropenije (vrednost nevtrofilcev <1,5 x 109/l) je 4,9 % (2,5 pojavov bolezni na 100 bolnikov-let).
The observed mean (SD) activity time profile following a single dose of ALPROLIX in patients with severe haemophilia B is shown below (see Table 6).
Časovni profil opažene povprečne (SD) aktivnosti po enem odmerku zdravila ALPROLIX pri bolnikih s hudo hemofilijo B je prikazan spodaj (glejte preglednico 4).
The observed pattern of increased risk may be due to an earlier diagnosis of breast cancer in COC users, the biological effects of COCs or a combination of both.
Opaženo povečano tveganje bi lahko bilo posledica zgodnejše diagnoze raka dojke pri uporabnicah KPK, bioloških učinkov KPK ali pa kombinacije obeh dejavnikov.
the observed pharmacokinetic
opažene farmakokinetične
The observed signs and symptoms for overdose were consistent with the known undesirable events associated with topotecan (see section 4.8).
Za preveliko odmerjanje topotekana ne poznamo antidota.
The observed treatment difference (95% CI) between ivacaftor and placebo was 10.7% (7.3, 14.1) (P<0.0001).
Cilj študije Razlika zaradi vrednost P Razlika zaradi vrednost P zdravljenjaa zdravljenjaa (95 % CI) (95 % CI)
The observed values of the peak concentrations are 9 fold greater than the IC50 of abacavir of 0.08 µg/ml or 0.26 µM when abacavir is given at 600 mg twice daily.
Vrednosti najvišjih koncentracij so devetkrat večje od IC50 abakavirja (0,08 µg/ml ali 0,26 µM) pri odmerku 600 mg abakavirja dvakrat dnevno.
The OBT was selected on the basis of the subject’s prior treatment history and baseline genotypic and phenotypic viral resistance measurements.
Optimizirana osnovna terapija je bila izbrana glede na anamnezo o preiskovančevi terapiji ter meritve izhodiščne genotipske in fenotipske odpornosti virusov.
The occurrence of activity-neutralising antibodies (inhibitors) is a very rare event in previously treated patients receiving factor IX-containing products.
Navzočnost protiteles, ki nevtralizirajo aktivnost (inhibitorji), je zelo redek pojav pri predhodno zdravljenih bolnikih, ki prejemajo zdravila, ki vsebujejo faktor IX.
The occurrence of anaemia (haemoglobin <10 g/dl) has been observed in up to 15% of chronic hepatitis C patients in clinical trials on the combined treatment of Pegasys with ribavirin.
Pojavnost anemije (hemoglobin < 10 g/dl) so opazili pri do 15 % bolnikov s kroničnim hepatitisom C v kliničnih preskušanjih kombiniranega zdravljenja zdravila Pegasys in ribavirina.
The occurrence of anaphylaxis remained rare between the double blind and long-term open-label experience.
Pojavnost anafilaksije je med dvojno slepim in dolgotrajnim odprtim obdobjem ostala redka.
The occurrence of headache, dizziness or blurred vision following administration of aclidinium bromide (see section 4.8) may influence the ability to drive or to use machinery.
Pojav glavobola, omotice ali zamegljenega vida po dajanju aklidinijevega bromida (glejte poglavje 4.8) lahko vpliva na sposobnost vožnje ali upravljanja s stroji.
The occurrence of osteosarcoma only occurred at doses that produced systemic exposures > 27-times higher than that observed in humans at the 100 micrograms dose.
Osteosarkom se je pojavil le pri odmerkih, ki so povzročili sistemsko izpostavitev, ki je bila  27-krat večja od izpostavitve pri človeku po odmerku 100 g.
The occurrence of these events may be linked to the patients’ disease evolution.
Naštete pojave bi lahko povezali z napredovanjem bolezni pri teh bolnikih.
The odd numbers, after the number 1, are shown as full lines.
Liha števila od številke 1 dalje so prikazana kot polne črte.
The odd numbers, after the number one, are shown as full lines.
Liha števila, ki so večja od 1, so prikazana z celo črto.
The oedema rates for comparator groups (sulphonylurea, metformin) were 2 – 5%.
Stopnje pojavnosti edemov primerjalnih skupin (sulfonilsečnina, metformin) so bile 2–5 %.
The oedema rates for comparator groups (sulphonylurea, metformin) were 2-5%.
Stopnje pojavnosti edemov primerjalnih skupin (sulfonilsečnina, metformin) so bile 2–5%.
The oedema rates for comparator groups (sulphonylurea, metformin) were 2–5%.
Delež edemov v skupinah s primerjalnim zdravilom (sulfonilsečnina, metformin) je bil od 2 do 5 %.
The oedema rates for comparator groups (sulphonylurea, metformin) were 2–5%.
Stopnje pojavnosti edemov primerjalnih skupin (sulfonilsečnina, metformin) so bile 2-5 %.
The oedema rates for comparator groups (sulphonylurea, metformin) were 2–5%.
Stopnje pojavnosti edemov primerjalnih skupin (sulfonilsečnina, metformin) so bile 2–5 %.
The oedema related events (peripheral oedema, generalised oedema, and oedema) were consistently lower in patients who received Twynsta as compared to patients who received amlodipine 10 mg.
Z edemom povezani dogodki (periferni edem, generalizirani edem in edem) so bili dosledno manj pogosti pri bolnikih, ki so jemali zdravilo Twynsta, kot pri bolnikih, ki so jemali amlodipin v odmerkih po 10 mg.
The off-white, oval tablets are imprinted with “Renagel 400” on one side.
Sivobele ovalne tablete imajo na eni strani natisnjeno oznako „Renagel 400“.
The off-white, oval tablets are imprinted with “Renagel 800” on one side.
Sivobele ovalne tablete imajo na eni strani natisnjeno oznako „Renagel 800“.
The off-white, oval tablets are imprinted with “SH800” on one side.
Sivobele ovalne tablete imajo na eni strani natisnjeno oznako “SH800”.
The OHSS may become severe with clearly enlarged ovaries, decreased urine production, weight gain, difficulty breathing or fluid in your stomach or chest.
Sindrom OHSS lahko postane resen z vidno povečanimi jajčniki, zmanjšanim proizvajanjem urina, povečanjem telesne mase, oteženim dihanjem ali tekočino v trebuhu ali prsnem košu.
The OHSS may become severe with clearly enlarged ovaries, decreased urine production, weight gain, difficulty in breathing and possible fluid accumulation in your stomach or chest.
OHSS lahko postane resen z izrazito povečanimi jajčniki, zmanjšanim nastajanjem urina, s pridobivanjem telesne mase, težavami dihanja in morebitnim nabiranjem tekočine v trebuhu ali prsnem košu.
The OHSS may become severe with clearly enlarged ovaries, decreased urine production, weight gain, difficulty in breathing and/or possible fluid accumulation in your stomach or chest.
OHSS lahko postane resen z izrazito povečanimi jajčniki, zmanjšanim nastajanjem urina, s pridobivanjem telesne mase, težavami dihanja in/ali morebitnim nabiranjem tekočine v trebuhu ali prsnem košu.
The olanzapine in Zypadhera is presented as a ‘pamoate’ salt, which makes the olanzapine less soluble.
Olanzapin v zdravilu Zypadhera je v obliki soli pamoata, zaradi česar je manj topen.
The Omnitrope cartridges should only be used with the special Omnitrope injection device.
Zdravilo Omnitrope v obliki vložkov se lahko uporablja le skupaj s posebno napravo za vbrizgavanje zdravila Omnitrope.
The on-demand treatment of acute bleeds or breakthrough bleeds with NovoThirteen has not been studied in clinical trials.
V kliničnih preskušanjih niso raziskali zdravljenja akutnih krvavitev ali vmesnih krvavitev z uporabo zdravila NovoThirteen po potrebi.
The once daily dosing regimen of Viramune immediate-release should not be continued beyond 28 days at which point in time an alternative treatment should be sought due to the possible risk of underexposure and resistance.
Režim zdravljenja enkrat na dan z zdravilom Viramune s takojšnjim sproščanjem sme trajati največ 28 dni, nato je treba poiskati alternativni način zdravljenja, zaradi uporabe majhnega odmerka zdravila in s tem možnega tveganja za razvoj odpornosti.
The once daily regimen of abacavir is supported by a 48 weeks multi-centre, double-blind, controlled study (CNA30021) of 770 HIV-infected, therapy-naïve adults.
Režim odmerjanja abakavirja enkrat na dan podpira multicentrična, dvojno slepa, nadzorovana študija, ki je pri 770 z virusom HIV okuženih, predhodno še nezdravljenih odraslih bolnikih trajala 48 tednov (CNA30021).
The once daily Viramune immediate-release lead-in dosing regimen should not be continued beyond 28 days at which point in time an alternative treatment should be sought due to the possible risk of underexposure and resistance.
Uvajalni režim odmerjanja zdravila Viramune s takojšnjim sproščanjem ne sme trajati dlje od 28 dni, nato je potrebno poiskati alternativni način zdravljenja zaradi izpostavljenosti premajhnemu odmerku zdravila in s tem možnemu tveganju za razvoj odpornosti.
The once weekly dose of romiplostim should be increased by increments of 1 μg/kg until the patient achieves a platelet count ≥ 50 x 109/l.
Odmerek romiplostima enkrat na teden je treba povečevati po 1 µg/kg, dokler bolnik ne doseže števila trombocitov ≥ 50 x 109/l.
The one-month standard pack contains 56 x 30 mg tablets.
Enomesečno standardno pakiranje vsebuje 56 x 30 mg tablet.
The ones marked may be related to busulfan.
Neželeni učinki, označeni z *, so lahko povezani z busulfanom.
The only adverse event reported to date was hypotension.
Edini neželeni učinek, ki so ga prijavili doslej, je bil hipotenzija.
The only adverse reactions commonly leading to discontinuation of Tasmar in clinical trials was diarrhoea (see section 4.4).
Edini neželeni učinek, ki je pogosto vodil k prekinitvi jemanja zdravila Tasmar v kliničnih preskušanjih, je bil diareja (glejte poglavje 4.4).
The only common adverse reaction observed following Cinryze infusion in clinical studies was rash; descriptions of rash characteristics were non-specific, but were typically described as involving the upper extremities, chest, abdomen, or injection site.
Edini pogosti neželeni učinek, ki so ga opazili po infuziji zdravila Cinryze v kliničnih študijah, je bil izpuščaj; njegove značilnosti so bile po opisih sodeč nespecifične, so ga pa značilno opisovali po zgornjih udih, prsih, trebuhu ali mestu injiciranja.
The only complication reported in connection with an overdose was a slight transient increase in blood pressure in a 16 year-old patient receiving 24 mg rFVIIa instead of 5.5 mg.
Edini zaplet, opisan v povezavi s prevelikim odmerjanjem, je bilo rahlo prehodno zvišanje krvnega tlaka pri 16- letnem bolniku, ki je dobil 24 mg rFVIIa namesto 5,5 mg.
The ONLY other solutions that can be administered through the same line are 0.9% Sodium Chloride Injection, Lactated Ringer’s Injection, Dextrose or Dextrose and Saline mixtures.
EDINE raztopine, ki jih lahko dajate po istemkatetru, so 0,9 % raztopina natrijevega klorida, raztopina Ringerjevega laktata, raztopina dekstroze ali raztopina dekstroze in fiziološke raztopine.
The ONLY other solutions that can be administered through the same line are 0.9% Sodium Chloride Injection, Lactated Ringer’s Injection, Dextrose or Dextrose and Saline mixtures.
EDINE raztopine, ki se jih sme dajati po istem katetru, so 0,9 % raztopina natrijevega klorida, raztopina Ringerjevega laktata, raztopina dekstroze ali raztopina dekstroze in fiziološke raztopine.
The only pharmacodynamic effect was a small (3.5 bpm) increase in heart rate.
Edini farmakodinamični učinek je bil manjše povišanje srčne frekvence (za 3,5 utripa na minuto).
The only safety concerns for human use derived from animal studies of salmeterol and fluticasone propionate given separately were effects associated with exaggerated pharmacological actions.
S študijami na živalih z ločenim dajanjem salmeterola in flutikazonpropionata so ugotovili, da edino skrb glede varnosti uporabe pri ljudeh predstavljajo učinki, povezani s pretiranim farmakološkim delovanjem.
The onset of action of caffeine from caffeine citrate is within minutes of commencement of infusion.
Začetek delovanja kofeina iz kofeinijevega citrata je v nekaj minutah po uvedbi infundiranja.
The onset of action of Cosentyx 150 mg occurred as early as Week 1 for ASAS 20 and Week 2 for ASAS 40 (superior to placebo) in AS Study 2.
V 2. študiji ankilozirajočega artritisa je zdravilo Cosentyx v odmerku 150 mg glede na odziv ASAS 20 začelo delovati že v 1. tednu, glede na odziv ASAS 40 pa v 2. tednu (bilo je boljše od placeba).
The onset of action of Cosentyx occurred as early as Week 2.
Zdravilo Cosentyx je začelo delovati že v 2. tednu zdravljenja.
The onset of action of Duaklir Genuair was comparable to the effect of the fast-acting β2-agonist formoterol 12 micrograms.
Začetek delovanja zdravila Duaklir Genuair je primerljiv z učinkom hitro delujočega agonista β2 formoterola 12 mikrogramov.
The onset of efficacy is within 8 hours for fleas (C. felis) and 12 hours for ticks (I. ricinus).
Učinkovanje na bolhe (C. felis) se začne v 8 urah po pritrditvi in na klope (I. ricinus) v 12 urah po pritrditvi.
The onset of immunity (induction of anti-GnRF antibodies) can be expected within 1 week post second vaccination.
Začetek imunosti (indukcija proti-GnRF protiteles) se lahko pričakuje znotraj enega tedna po drugem cepljenju.
The onset of immunity is established as two weeks after vaccination.
Imunost se razvije dva tedna po osnovnem cepljenju.
The onset of neuromuscular blockade may be prolonged up to approximately 4 minutes, and the duration of neuromuscular blockade may be shortened up to approximately 15 minutes after re- administration of rocuronium 1.2 mg/kg within 30 minutes after sugammadex administration.
Pri ponovni uporabi 1,2 mg/kg rokuronija v času 30 minut po uporabi sugamadeksa se lahko začetek delovanja živčnomišične blokade podaljša do približno 4 minute in čas trajanja živčnomišične blokade skrajša do približno 15 minut.
The onset of protection is from 2 weeks and the protection extends to 9 weeks.
Zaščita nastopi od drugega tedna dalje in traja do 9 tednov.
The onset of protection is from 4 days.
Zaščita nastopi od četrtega dneva dalje.
The onset of pulmonary signs such as cough, fever and dyspnoea in association with radiological signs of pulmonary infiltrates and deterioration in pulmonary function may be preliminary signs of Acute Respiratory Distress Syndrome (ARDS).
Začetek pojavljanja pljučnih znakov, kot so na primer kašelj, zvišana telesna temperatura in dispneja ob hkratnih radioloških znakih pljučnih infiltratov in ob slabšanju delovanja pljuč, lahko pomeni začetek sindroma akutne dihalne stiske (ARDS- Acute Respiratory Distress Syndrome).